Andere talen GRI Bio, Inc.

Aandelen

GRI

US3622AW3040

slotkoers Nasdaq Andere beurzen 00:00:00 02-07-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,64 ^USD	-13,68%		-10,38%	-95,32%

02/07	GRI Bio, Inc. Kondigt de publicatie aan van positieve preklinische gegevens van het hoofdprogramma GRI-0621 in het American Journal of Respiratory and Critical Care Medicine	CI
21/05	GRI Bio, Inc presenteert positieve preklinische gegevens van de pijplijn van NKT-celmodulatoren in ontwikkeling voor de behandeling van systemische lupus erythematosus	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

GRI Bio, Inc. Announces Publication of Positive Preclinical Data from Lead Program GRI -0621 in the American Journal of Respiratory and Critical Care Medicine	02/07
GRI Bio, Inc Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus	21/05
GRI Bio, Inc. Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis	20/05
GRI Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T Cell Modulators with Issuance of Korea Patent	16/04
GRI Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
GRI Bio, Inc. Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom	04/03
GRI Bio's Board Approves 1-for-7 Reverse Stock Split to Regain Nasdaq Compliance	26/01
GRI Bio Announces Reverse Stock Split	26/01
GRI Bio begins patent enrollment for Phase 2a study of GRI-0621 for IPF treatment	06/12
GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)	05/12
GRI Bio, Inc. Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for Treatment of Idiopathic Pulmonary Fibrosis	05/12
GRI Bio Secures FDA Clearance for Investigational New Drug Application for Pulmonary Fibrosis Treatment	27/11
GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)	27/11
GRI Bio, Inc. Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis	27/11
GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update	15/11
GRI Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases	31-10-23
GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference	19-10-23
GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression	17-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen GRI Bio, Inc.

Aandelen

GRI

US3622AW3040

Andere talen

Filters